IAM
Iambic Therapeutics, Inc. · NASDAQ:IAM
13.43 USD−0.8500 −5.95%
Iambic Therapeutics, Inc. (NASDAQ:IAM) last traded at 13.43 USD, down 5.95% on the day. Over the past year the stock is down 16.84%. Its 52-week range is 12.39 to 25.00. It is in the Health Technology sector (Biotechnology).
Key statistics
Open13.10
Day range12.39 – 13.57
52-week range12.39 – 25.00
Volume476.85 K
Average volume (10 days)721.96 K
Market cap636.59 M
Dividend yield0.00%
Performance
−7.38%1 week
−16.84%1 month
−16.84%3 months
−16.84%6 months
−16.84%Year to date
−16.84%1 year
Technical rating
Strong sell
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Iambic Presents Updated Iam1363 Clinical Data At Esmo 2026, Showing Durable Responses With A Favorable Tolerability Profile In Heavily Pretreated Participants With Her2-Driven CancersReuters · 26 Oct 2026
- Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven CancersBusinessWire · 26 Oct 2026
- Iambic Therapeutics, Inc. (IAM) Posts Updated IAM1363 Phase 1/1b DataTradingView · 26 Oct 2026
- Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, ToastSeeking Alpha · 19 Oct 2026
- Weekly Recap: Iambic Therapeutics IPO $150M and Unproven therapy risksTradingView · 19 Oct 2026
- Nvidia-backed drug discovery firm Iambic climbs on trading debutSeeking Alpha · 15 Oct 2026
- Iambic Therapeutics prices 9.38M share IPO at $16.00/shareSeeking Alpha · 15 Oct 2026
- Iambic Therapeutics' 9.4M-Share IPO Prices at $16 a ShareDow Jones Newswires · 14 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.